A Phase 3 interventional study of 0.25mg DRSP / 0.5mg E2 (BAY86-4891) and 0.5mg NETA / 1.0mg E2 (Activella) in Postmenopause, sponsored by Bayer. Completed at 59 sites in 8 countries. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-12-31.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing estradiol in Hot Flashes — none open to participants now, none under way, none of them phase 3. Estradiol · Hot Flashes.
Among the 13 studies testing estradiol in Hot Flashes, this one is the 4th largest by enrollment, is one of 4 that started in 2007, is one of 8 in phase 3, and was the 7th registered.
339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.
Browse Hot Flashes studies →None of the 13 studies testing estradiol in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →
Estradiol: first FDA approval 1954 (DELESTROGEN), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 40 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 9 · Phase 4 1
First in 2003; this study’s year is marked. 4 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 662 is above the median of 90 across 306 interventional studies indexed under Hot Flashes.
Median enrollment 431 across the 13 interventional studies. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 13 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
18 studies in Hot Flashes by Bayer: none open now, 1 under way, 1 of them phase 3. Of 17 finished, 7 (41%) have results posted.
Among the 18 studies in Hot Flashes by Bayer, this one is the 2nd largest by enrollment, is one of 3 that started in 2007, is one of 7 in phase 3, and was the 4th registered.
Bayer’s Hot Flashes studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing estradiol in Hot Flashes, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 18 in Hot Flashes:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study is designed to investigate the safety of the investigational product for the lining of the uterus (endometrium).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One capsule \[0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 13 cycles (28 days per cycle).
Drug: 0.25mg DRSP / 0.5mg E2 (BAY86-4891)
One capsule \[0.5mg norethisterone acetate/1.0mg 17β-estradiol (NETA/E2)\] per day taken orally for 13 cycles (28 days per cycle).
Drug: 0.5mg NETA / 1.0mg E2 (Activella)
Drug pages: Drospirenone · Estradiol
One capsule \[0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 13 cycles (28 days per cycle).
One capsule \[0.5mg norethisterone acetate/1.0mg 17β-estradiol (NETA/E2)\] per day taken orally for 13 cycles (28 days per cycle).
Number of Participants in the DRSP/E2 Group With an Assessment of Endometrial Hyperplasia or Worse at End of Study (EoS) (1 Year of Treatment)
The number of women who had a biopsy classified as 'hyperplasia or worse' at any time during the study. According to the protocol this endpoint was defined as primary for the DRSP/E2 group only.
Time frame: Up to one year
Number of Participants With Amenorrhea During Month 1 to 3 of Treatment
The women were to record daily in a diary, indicating 'no bleeding', 'spotting', 'light bleeding', 'normal bleeding' or 'heavy bleeding'. Women were considered to have amenorrhea if they had no bleeding and no spotting day within the given time interval.
Time frame: Month 1 to Month 3
Number of Participants With Amenorrhea During Month 10 to 12 of Treatment
The women were to record any bleeding daily in a diary, indicating 'no bleeding', 'spotting', 'light bleeding', 'normal bleeding' or 'heavy bleeding'. Women were considered to have amenorrhea if they had no bleeding and no spotting day within the given time interval.
Time frame: Month 10 to Month 12
Only non-hysterectomized, postmenopausal women could take part in this study. The women had to have symptoms requiring hormone therapy in the opinion of the investigator. An endometrial biopsy at screening was to show no evidence of endometrial hyperplasia or cancer.
| Milestone | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | 0.5mg NETA / 1.0mg E2 (Activella) |
|---|---|---|
| Started | 490 | 172 |
| Received treatment | 489 | 172 |
| Completed | 394 | 128 |
| Not completed | 96 | 44 |
| Withdrew: Adverse event | 41 | 26 |
| Withdrew: Withdrawal by subject | 20 | 9 |
| Withdrew: Protocol violation | 14 | 4 |
| Withdrew: Lost to follow-up | 11 | 3 |
| Withdrew: Personal reasons | 8 | 1 |
| Withdrew: Medication errors | 1 | 1 |
| Withdrew: Never received medication | 1 | 0 |
The number of women who had a biopsy classified as 'hyperplasia or worse' at any time during the study. According to the protocol this endpoint was defined as primary for the DRSP/E2 group only.
| Participants | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) |
|---|---|
| Number of Participants in the DRSP/E2 Group With an Assessment of Endometrial Hyperplasia or Worse at End of Study (EoS) (1 Year of Treatment) | 0 |
The women were to record daily in a diary, indicating 'no bleeding', 'spotting', 'light bleeding', 'normal bleeding' or 'heavy bleeding'. Women were considered to have amenorrhea if they had no bleeding and no spotting day within the given time interval.
| Participants | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | 0.5mg NETA / 1.0mg E2 (Activella) |
|---|---|---|
| Number of Participants With Amenorrhea During Month 1 to 3 of Treatment | 255 | 67 |
The women were to record any bleeding daily in a diary, indicating 'no bleeding', 'spotting', 'light bleeding', 'normal bleeding' or 'heavy bleeding'. Women were considered to have amenorrhea if they had no bleeding and no spotting day within the given time interval.
| Participants | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | 0.5mg NETA / 1.0mg E2 (Activella) |
|---|---|---|
| Number of Participants With Amenorrhea During Month 10 to 12 of Treatment | 280 | 89 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | — | 16/489 (3.3%) | 172/489 (35.2%) |
| 0.5mg NETA / 1.0mg E2 (Activella) | — | 6/172 (3.5%) | 63/172 (36.6%) |
| Event | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | 0.5mg NETA / 1.0mg E2 (Activella) |
|---|---|---|
| Deafness neurosensoryEar and labyrinth disorders | 0/489 | 1/172 |
| HyperparathyroidismEndocrine disorders | 0/489 | 1/172 |
| Retinal vascular thrombosisEye disorders | 0/489 | 1/172 |
| AppendicitisInfections and infestations | 0/489 | 1/172 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/489 | 1/172 |
| Grand mal convulsionNervous system disorders | 0/489 | 1/172 |
| LymphadenopathyBlood and lymphatic system disorders | 1/489 | 0/172 |
| Abdominal pain lowerGastrointestinal disorders | 1/489 | 0/172 |
| ConstipationGastrointestinal disorders | 1/489 | 0/172 |
| FaecalomaGastrointestinal disorders | 1/489 | 0/172 |
| Event | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | 0.5mg NETA / 1.0mg E2 (Activella) |
|---|---|---|
| HeadacheNervous system disorders | 32/489 | 7/172 |
| Breast painReproductive system and breast disorders | 21/489 | 10/172 |
| Postmenopausal haemorrhageReproductive system and breast disorders | 14/489 | 9/172 |
| InfluenzaInfections and infestations | 21/489 | 6/172 |
| Cervical dysplasiaReproductive system and breast disorders | 11/489 | 7/172 |
| NasopharyngitisInfections and infestations | 18/489 | 2/172 |
| DepressionPsychiatric disorders | 9/489 | 6/172 |
| Weight increasedInvestigations | 17/489 | 3/172 |
| Back painMusculoskeletal and connective tissue disorders | 17/489 | 2/172 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 16/489 | 4/172 |
| Age, Continuous(Years) | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | 0.5mg NETA / 1.0mg E2 (Activella) | Total |
|---|---|---|---|
| Mean | 53.5 ± 5.1 | 53.5 ± 4.5 | 53.5 ± 4.9 |
| Sex: Female, Male(Participants) | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | 0.5mg NETA / 1.0mg E2 (Activella) | Total |
|---|---|---|---|
| Female | 489 | 172 | 661 |
| Male | 0 | 0 | 0 |
| Body Mass Index (BMI)(kg/m^2) | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | 0.5mg NETA / 1.0mg E2 (Activella) | Total |
|---|---|---|---|
| Mean | 26.315 ± 4.851 | 26.020 ± 5.476 | 26.184 ± 5.008 |
| Number of participants with hysterectomy/oophorectomy(Participants) | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | 0.5mg NETA / 1.0mg E2 (Activella) | Total |
|---|---|---|---|
| Hysterectomized | 0 | 0 | 0 |
| Oophorectomized | 25 | 5 | 30 |
| Years since last menstruation at baseline(years) | 0.25mg DRSP / 0.5mg E2 (BAY86-4891) | 0.5mg NETA / 1.0mg E2 (Activella) | Total |
|---|---|---|---|
| Mean | 5.109 ± 4.528 | 4.807 ± 4.287 | 5.031 ± 4.465 |
The record gives a start of Aug 2007, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2012, 2 years 10 months after primary completion. A results delay was requested in Sep 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Drospirenone · Estradiol